补肾泄浊方联合厄贝沙坦片对早期糖尿病肾病患者C ys-C、H cy的影响及机制研究

Abstract
Figure/Table
References (16)
Related Citation (14)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Bushen Xiezhuo Prescription combined with Irbesartan Tablets in the treatment of early diabetic nephropathy and its influence on serum cystatin C (Cys C)and serum homocysteine(Hcy).Methods From January 2020 to January 2021,80 patients with early diabetic nephropathy treated in Department of Nephropathy of Jiujiang Hospital of Traditional Chinese Medicine in Jiangxi Province were selected and divided into the treatment group 1 and the treatment group 2 according to random number table method,40 cases in each group.A total of 10 healthy persons who took physical examination in Physical Examination Center of Jiujiang Hospital of Traditional Chinese Medicine in Jiangxi Province in the same period were selected as the control group.The treatment group 2 and the treatment group 1 were given intensive hypoglycemic treatment,diet therapy,exercise therapy,nutrition therapy and other basic treatment.The treatment group 1 was treated with Irbesartan Tablets on the basis of the basic treatment,and the treatment group 2 was treated with Bushen Xiezhuo Prescription on the basis of the treatment group 1.The levels of Cys C and Hcy of the three groups were observed,the symptom scores and related laboratory indexes of the treatment group 2 and the treatment group 1 before treatment and after three courses of treatment were recorded,and the traditional Chinese medicine symptom efficacy,clinical efficacy and the total incidence of adverse reactions of the treatment group 2 and the treatment group 1 were compared.Results There were significant differences in the levels of Cys C and Hcy among the three groups before treatment(P＜0.05).The levels of Cys C and Hcy in the treatment group 2 and the treatment group 1 were higher than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in the levels of Cys C and Hcy between the two groups before treatment(P＞0.05).The symptom scores of the treatment group 2 and the treatment group 1 after treatment were lower than those before treatment,the differences were statistically significant(P＜0.05).The symptom score of the treatment group 2 after treatment was lower than that of the treatment group 1,the difference was statistically significant(P＜0.05).The levels of Cys C,Hcy,microalbuminuria,D-dimer,fasting blood glucose,triglyceride,total cholesterol,serum creatinine(SCr),blood urea nitrogen(BUN),uric acid and C-reactive protein (CRP)in the treatment group 2 and the treatment group 1 after treatment were lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of Cys C,Hcy,microalbuminuria,D-dimer,fasting blood glucose,triglyceride,total cholesterol,SCr,BUN,uric acid and CRP in the treatment group 2 after treatment were lower than those in the treatment group 1,and the differences were statistically significant(P＜0.05).The total effective rate of traditional Chinese medicine syndrome in treatment group 2 was 92.50%,which was higher than that in treatment group 1(72.50%),and the difference was statistically significant(P＜0.05).The total effective rate of the treatment group 2 was 95.00%,which was higher than 72.50% of the treatment group 1,the difference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the treatment group 2 and the treatment group 1 (P＞0.05).Conclusion The combination of Bushen Xiezhuo Prescription and Irbesartan Tablets has a good therapeutic effect on patients with early diabetic nephropathy,that is,it improves the clinical efficacy and does not increase adverse reactions.It provides a new way of thinking for the treatment of early diabetic nephropathy with traditional Chinese and Western medicine.

Key words： Bushen Xiezhuo Prescription Irbesartan Tablets Early diabetic nephropathy Serum cystatin C Serum homocysteine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZONG Hai-tao
	LI Jin-hua
	LI Ya-ning

Cite this article:

ZONG Hai-tao,LI Jin-hua,LI Ya-ning. Application of Bushen Xiezhuo Prescription combined with Irbesartan Tablets on Cys-C and Hcy in patients with early diabetic nephropathy and study on its mechanism[J]. 中国当代医药, 2021, 28(31): 14-18.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I31/14

[1]	张晴霄，朱斌.新型降糖药对糖尿病肾病的作用进展[J].中国中西医结合肾病杂志，2020，21（10）：927-930.
[2]	曹国霞，叶维维.HCY、CysC、U-mAlb联合指标检测在早期糖尿病肾病中的诊断价值[J].医学检验与临床，2020，31（6）：46-48.
[3]	张杨.血清胱抑素C与肌酐、尿素氮联合检测在肾功能损害诊断中的运用分析[J].系统医学，2020，5（23）：31-33.
[4]	钟凯丽.胱抑素C、血肌酐联合尿肌酐、尿素氮检测对代谢综合征患者早期肾损害的诊断价值[J].检验医学与临床，2019，16（21）：3204-3207.
[5]	王蓉，贺婷婷，钱文嘉.糖尿病肾病患者血清同型半胱氨酸、白细胞介素-6水平与肾脏功能及预后的关系[J].检验医学与临床，2019，16（13）：1883-1885.
[6]	柳占富.中西医结合治疗早期糖尿病肾病患者的临床疗效[J].吉林医学，2020，41（11）：2743-2744.
[7]	中华医学会.临床诊疗指南·肾脏病学分册[M].北京：人民卫生出版社，2011.
[8]	中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准（试行方案）[J].上海中医药杂志，2007，41（7）：7-8.
[9]	郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[10]	吉林霞，伍小琴.糖尿病肾病患者血清Cys C、NGAL、ACR水平及临床意义[J].标记免疫分析与临床，2020，27（3）：383-386.
[11]	陈海兰，郭海霞，高宇.早期糖尿病肾病患者血清Cys-C水平与 eGFR 的相关性[J].承德医学院学报，2019，36（3）：211-213.
[12]	黄刚，陈永刚，肇玉博.糖尿病肾病血清胱抑素C的检测及临床意义[J].现代中西医结合杂志，2014，23（4）：424-425.
[13]	李志国.血清同型半胱氨酸、胱抑素C、腺苷脱氨酶及尿β2微球蛋白联合检测在糖尿病肾病的应用[J].临床研究，2020，28（5）：143-144.
[14]	杨征，吴静宇，凌爱华.血清同型半胱氨酸与血清胱抑素C联合检测在社区筛查早期糖尿病肾病中的应用[J].糖尿病新世界，2019，22（2）：57-60.
[15]	张素英，田伟伟，李瑞静，等.消渴Ⅱ号方联合厄贝沙坦片治疗早期糖尿病肾病的临床疗效及对患者炎症因子的影响[J].河北中医，2019，41（4）：551-556.
[16]	姜宝红.糖尿病肾病防治药物研究[D].沈阳：沈阳药科大学，1998.